| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2011 | US7879807 Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
| 02/01/2011 | US7879806 1-chloro-4-( beta -D-glucopyranos-1-yl)-2-[4-((1R,2R)-2-hydroxy-cyclopent-1-yloxy)-benzyl]-benzene; metabolic disorders such as diabetes, metabolic acidosis or ketosis, reactive hypoglycaemia, hyperinsulinaemia; sodium-dependent glucose cotransporter SGLT2 inhibitors |
| 02/01/2011 | US7879791 Regulation of T cell-mediated immunity by tryptophan |
| 02/01/2011 | US7879609 Regulatory segments of the human gene for telomerase reverse transcriptase |
| 02/01/2011 | US7879577 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 02/01/2011 | US7879570 Nucleic acid and corresponding protein entitled 184P1E2 useful in treatment and detection of cancer |
| 02/01/2011 | US7879558 Diagnostic markers for ischemia |
| 02/01/2011 | US7879547 Method of detecting the presence of asthma or allergies in a patient |
| 02/01/2011 | US7879375 Pharmaceutical composition |
| 02/01/2011 | US7879373 comprises curcuminoid and an essential oil of turmeric; curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin and essential oil of turmeric comprises about 45% ar-turmerone |
| 02/01/2011 | US7879366 Halogenated composition, method for preparing same and uses thereof |
| 02/01/2011 | US7879365 Zinc salt compositions for the prevention of dermal and mucosal irritation |
| 02/01/2011 | US7879364 Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 02/01/2011 | US7879362 Oral pharmaceutical compositions with controlled release and prolonged absorption |
| 02/01/2011 | US7879359 Compositions for preparing external carbon dioxide agents |
| 02/01/2011 | US7879358 Parkinson's disease therapy; aqueous solution mixture with sugar |
| 02/01/2011 | US7879357 Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
| 02/01/2011 | US7879356 AB block polymers, comprising a polylactone part made from monomers such as lactic acid, and B is derived from hydroxyl, amine, or carboxyl terminated compound endcapped with nonreactive group; storage stablity; anti-adhesions |
| 02/01/2011 | US7879349 cyanocobalamin at 0.5%, citric acid 0.12%, sodium citrate 0.32%, glycerin 2.23%, benzalkonium chloride 0.02% and 96.79% water;elevating the vitamin B12 levels in the cerebral spinal fluid; intranasally spray |
| 02/01/2011 | US7879347 skin cosmetics for inducing lipolytic activity; reform obese constitution by promoting shrinkage of general or topical fatty tissues, prevents swelling; odor and taste free; chewing gums |
| 02/01/2011 | US7879337 Mutant porcine reproductive and respiratory syndrome virus |
| 02/01/2011 | US7879335 Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| 02/01/2011 | US7879317 biocompatible amphiphilic copolymer of hydrophilic and hydrophobic blocks, and a polylactic acid derivative having a terminal carboxy metal salt; hydrophilic outer shell and hydrophobic inner core physically trap hydrophobic drug; prolonged retention time in the bloodstream on delivery |
| 02/01/2011 | US7879315 such as inositol phosphoric acid esters (phytic acid), polyphenols (Perilla frutescen var. crispa polyphenols), perilla extract comprising rosmarinic acid, phosphoric acids, edetic acid salts, tartaric acid, malic acid, citric acid, and glycolic acid |
| 02/01/2011 | US7879023 System for perfusion management |
| 02/01/2011 | CA2688915C Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 02/01/2011 | CA2641952C Treatment of early stage idiopathic pulmonary fibrosis |
| 02/01/2011 | CA2630040C Heterocycle-substituted 3-alkyl azetidine derivatives |
| 02/01/2011 | CA2609634C Tetracyclic azapyrazinoindolines as 5-ht2 ligands |
| 02/01/2011 | CA2560547C Formamide derivatives useful as adrenoceptor |
| 02/01/2011 | CA2558429C Compositions and methods for preventing or treating an inflammatory response |
| 02/01/2011 | CA2555633C Non-nucleoside reverse transcriptase inhibitors |
| 02/01/2011 | CA2551529C Amide derivative and medicine |
| 02/01/2011 | CA2547332C Companion animal compositions comprising short chain oligofructose |
| 02/01/2011 | CA2543324C Rapidly disintegrating films for delivery of pharmaceutical or cosmetic agents |
| 02/01/2011 | CA2536728C Method and composition for treating rhinitis |
| 02/01/2011 | CA2509554C Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
| 02/01/2011 | CA2502633C 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives |
| 02/01/2011 | CA2494091C Substituted furo [2,3-b| pyridine derivatives |
| 02/01/2011 | CA2488220C Medicament with delayed active constituent release containing 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol |
| 02/01/2011 | CA2484935C Amide derivatives as inhibitors of the enzymatic activity of renin |
| 02/01/2011 | CA2483110C Use of a mare milk concentrate dried on a biologically inert, highly disperse matrix |
| 02/01/2011 | CA2483002C New pharmaceutical composition |
| 02/01/2011 | CA2482972C The use of hydroxypyridone-derivatives in wound healing |
| 02/01/2011 | CA2481560C Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| 02/01/2011 | CA2481468C Medicaments containing betamimetic drugs and a novel anticholinesterase drug |
| 02/01/2011 | CA2481055C Combinations of quinolinone derivatives and 5-fu or cpt 11 |
| 02/01/2011 | CA2477881C Formoterol superfine formulation |
| 02/01/2011 | CA2476833C Novel methylated cyclodextrin complexes |
| 02/01/2011 | CA2476298C Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 02/01/2011 | CA2474004C Formulations comprising triazoles and alkoxylated amines |
| 02/01/2011 | CA2467097C The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| 02/01/2011 | CA2466657C Soluble drug extended release system |
| 02/01/2011 | CA2466140C Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators |
| 02/01/2011 | CA2464689C Modified release tamsulosin tablets |
| 02/01/2011 | CA2461218C Muscarinic agonists |
| 02/01/2011 | CA2459449C Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia |
| 02/01/2011 | CA2454120C Taxol enhancer compounds |
| 02/01/2011 | CA2453747C Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use |
| 02/01/2011 | CA2453442C Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 02/01/2011 | CA2451206C Urea derivatives with antiproteolytic activity |
| 02/01/2011 | CA2447878C 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis |
| 02/01/2011 | CA2446994C Prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/01/2011 | CA2446812C Novel sulfonate-substituted pyrazolopyridine derivatives |
| 02/01/2011 | CA2446386C 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/01/2011 | CA2442917C Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| 02/01/2011 | CA2442809C Promoter for saccharide uptake |
| 02/01/2011 | CA2442414C Use of rare earth compounds for the prevention of kidney stone disease |
| 02/01/2011 | CA2427375C Pharmaceutical dronedarone composition for parenteral administration |
| 02/01/2011 | CA2425172C Methods of decreasing or preventing pain using spicamycin derivatives |
| 02/01/2011 | CA2418656C Proline derivatives and use thereof as drugs |
| 02/01/2011 | CA2406212C Substituted styryl benzylsulfones for treating proliferative disorders |
| 02/01/2011 | CA2405508C Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 02/01/2011 | CA2403691C The use of cocoa procyanidins combined with acetylsalicylic acid as an anti-platelet therapy |
| 02/01/2011 | CA2403424C Flavone derivatives, preparation method and use as medicines |
| 02/01/2011 | CA2402589C Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa |
| 02/01/2011 | CA2398053C Method for the fractionation of oil and polar lipid-containing native raw materials |
| 02/01/2011 | CA2388377C Medication for the treatment of chronic fatigue syndrome and related symptoms |
| 02/01/2011 | CA2388369C Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| 02/01/2011 | CA2382887C Immunopotentiating compositions |
| 02/01/2011 | CA2382337C Composition for treatment of infections of humans and animals |
| 02/01/2011 | CA2380857C Substituted 2-dialkylaminoalkylbiphenyl derivatives |
| 02/01/2011 | CA2380550C C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/01/2011 | CA2369560C Agent for prophylaxis and treatment of liver disease |
| 02/01/2011 | CA2364342C Agglomerates by crystallisation |
| 02/01/2011 | CA2351707C Crystal modification b of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo-[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid |
| 02/01/2011 | CA2342133C Ophthalmic formulations |
| 02/01/2011 | CA2320116C 2-aminoquinoline derivatives having d4-agonistic activity |
| 02/01/2011 | CA2315717C Inhibition of raf kinase using substituted heterocyclic ureas |
| 02/01/2011 | CA2315713C Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
| 02/01/2011 | CA2313653C Prevention and/or treatment of allergic conditions |
| 02/01/2011 | CA2286385C Quinoline derivatives, having in particular antiviral properties, preparation and biological applications thereof |
| 02/01/2011 | CA2274902C Submucosa extracts |
| 02/01/2011 | CA2222279C Hypoxia inducible factor-1 and method of use |
| 02/01/2011 | CA2219978C Method for inhibiting neoplastic disease in mammals |
| 02/01/2011 | CA2189143C A method of modifying angiotensin receptor activity for treatment of premenstrual syndrome and mediation of pain |
| 02/01/2011 | CA2125472C A method for generation of antibodies to cell surface molecules |
| 01/27/2011 | WO2011011783A1 Spectinamides as anti-tuberculosis agents |
| 01/27/2011 | WO2011011766A1 Galantamine amino acid and peptide prodrugs and uses thereof |
| 01/27/2011 | WO2011011733A2 Factor replacement therapy |